TICKERNERD
Menu
LXRXLXRXHealthcare · Biotechnology

LXRX Stock Forecast: Lexicon Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$2.32
−0.85% on the day

The 5 Wall Street analysts covering Lexicon Pharmaceuticals, Inc. hold a median 12-month price target of $3.1 — +33.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 69 of 100 as at 15 Aug 2026 — in the upper half.

Market cap
$1.0B
Ticker Nerd rank
69 / 100
Median analyst target
$3.10
Analysts covering
5
Total return, dividends reinvested
1W
−6.1%
1M
+9.4%
YTD
+101.7%
1Y
+96.6%
From 52W high
−12.1%
From 52W low
+116.8%
$1.07
$2.64
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

LXRX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Lexicon Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
69 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
93
Quality
88
Value
78
Volatility
51
Growth
49
Issuance
46
Size
45
Revisions
44
Accruals
42

Momentum (93): The shares have been drifting up relative to others.

Accruals (42): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

LXRX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on LXRX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1.00$2.00$3.00$4.00$5.00$6.00Oct 25Jan 26Apr 26Jul 26LXRXHigh $6.00Median $3.10Low $2.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says5 analysts
3 Buy2 Hold0 Sell
Low $2.00Median $3.10High $6.00

The green dot is the last close — the median target sits +33.6% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
11 May 2026CitigroupMaintainsBuy$2.30 → $3.10
23 Mar 2026HC Wainwright & Co.ReiteratesBuy—
10 Mar 2026CitigroupMaintainsBuy—
5 Mar 2026HC Wainwright & Co.MaintainsBuy—
2 Sept 2025HC Wainwright & Co.ReiteratesBuy—
7 Aug 2025CitigroupMaintainsBuy—
24 June 2025HC Wainwright & Co.ReiteratesBuy—
28 Mar 2025HC Wainwright & Co.ReiteratesBuy—
7 Mar 2025HC Wainwright & Co.ReiteratesBuy—
7 Mar 2025NeedhamReiteratesHold—
7 Mar 2025Piper SandlerMaintainsOverweight—
4 Mar 2025Leerink PartnersDowngradeMarket Perform—
3 Mar 2025HC Wainwright & Co.ReiteratesBuy—
3 Mar 2025NeedhamReiteratesHold—
29 Jan 2025HC Wainwright & Co.ReiteratesBuy—
29 Jan 2025NeedhamReiteratesHold—
23 Dec 2024NeedhamReiteratesHold—
25 Nov 2024NeedhamReiteratesHold—
22 Nov 2024NeedhamReiteratesHold—
13 Nov 2024HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. LXRX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

LXRX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
0
Fundamentals

Lexicon Pharmaceuticals, Inc. (LXRX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−16.5×

Cheaper than 95% of US stocks

Price / sales
24.9×

Cheaper than 8% of US stocks

Price / book
5.9×

Cheaper than 18% of US stocks

EV / EBITDA
−16.7×

Cheaper than 88% of US stocks

Growth & margins
Revenue growth (YoY)
−97.6%

Higher than 2% of US stocks

Earnings growth (YoY)
−97.6%

Higher than 2% of US stocks

Gross margin
94.4%

Higher than 98% of US stocks

Operating margin
−3835.3%

Higher than 3% of US stocks

Net margin
−147.4%

Higher than 4% of US stocks

Returns & dividend
Return on equity
−40.2%

Higher than 24% of US stocks

Return on assets
−14.3%

Higher than 23% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

LXRX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
LXRXLexicon Pharmaceuticals, Inc.$1.0B
69
AVTXAvalo Therapeutics, Inc.$1.0B
42
WVEWave Life Sciences, Inc.$1.0B
15
SVRASavara, Inc.$1.1B
33
ANNXAnnexon, Inc.$1.0B
38
SANASana Biotechnology, Inc.$1.1B
32
ARDXArdelyx, Inc.$986.5M
54

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Lexicon Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest LXRX news & analysis

Lexicon Pharmaceuticals Q2 Earnings Call Highlights

MarketBeat · 6 Aug 2026neutral

Lexicon Pharmaceuticals reported a wider second-quarter loss as revenue declined sharply year over year. The company highlighted completed enrollment in its Phase III SONATA-HCM trial and outlined plans to resubmit a new drug application for ZYNQUISTA in type 1 diabetes during the fourth quarter.

Why it matters — A LXRX watcher would care because the Phase III enrollment milestone and the planned ZYNQUISTA NDA resubmission are key regulatory steps for the company's pipeline despite the weaker quarterly financial results.

Lexicon Pharmaceuticals, Inc. (LXRX) Q2 2026 Earnings Call Transcript

Seeking Alpha · 6 Aug 2026neutral

Lexicon Pharmaceuticals, Inc. (LXRX) held its Q2 2026 earnings call, and a transcript of the call was published by Seeking Alpha. The item reports the availability of the company's second-quarter financial results and management commentary from the call.

Why it matters — An LXRX watcher would look to the Q2 2026 earnings call transcript for the company's latest financial results and management's commentary on its operations and outlook.

Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Lags Revenue Estimates

Zacks Investment Research · 6 Aug 2026negative

Lexicon Pharmaceuticals reported a Q2 loss of $0.06 per share, in line with the Zacks Consensus Estimate and down from earnings of $0.01 per share a year ago. Revenue fell short of analyst expectations, per the report's headline.

Why it matters — The quarter shows a year-over-year swing from profit to loss and a revenue miss, which matters for watchers tracking LXRX's recent financial performance.

Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates

GlobeNewsWire · 6 Aug 2026positive

Lexicon Pharmaceuticals reported financial results for the three months ended June 30, 2026, and provided clinical updates. The company announced completed enrollment in the Phase 3 SONATA-HCM study with top-line data expected in Q1 2027, said NDA resubmission activities for ZYNQUISTA in type 1 diabetes are nearing completion, and noted Novo Nordisk's Phase 1 clinical development of LX9851 is ongoing.

Why it matters — The update covers progress on several key clinical and regulatory milestones for LXRX, including the SONATA-HCM trial timeline, the ZYNQUISTA resubmission, and the LX9851 partnership program.

Lexicon Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026

GlobeNewsWire · 30 July 2026neutral

Lexicon Pharmaceuticals announced it will release its second quarter 2026 financial results on August 6, 2026, before market open, followed by a conference call and webcast at 8:30 a.m. ET that day to discuss the results and provide a business update.

Why it matters — Investors and analysts tracking LXRX will learn the company's latest financial performance and receive an update on its business outlook.

FAQ

Frequently asked questions about LXRX stock

What is the LXRX stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Lexicon Pharmaceuticals, Inc. have a median 12-month price target of $3.1, with estimates ranging from $2 to $6. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is LXRX stock a buy right now?

Of the 5 analysts covering Lexicon Pharmaceuticals, Inc., 3 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Lexicon Pharmaceuticals, Inc. 69 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank LXRX?

As at 15 Aug 2026, Lexicon Pharmaceuticals, Inc. ranks 69 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (93 of 100).

Will LXRX stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +33.6% from the last close, and Ticker Nerd's factor model ranks Lexicon Pharmaceuticals, Inc. 69 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the LXRX stock forecast for 2030?

No analyst covering Lexicon Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LXRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $6 over the next 12 months.

How has LXRX stock performed over the past year?

Lexicon Pharmaceuticals, Inc. returned +96.6% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Lexicon Pharmaceuticals, Inc. do?

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases, particularly in cardiometabolic and neurological areas.

What is the latest news on LXRX?

The most recent item we track (MarketBeat, 6 Aug 2026): "Lexicon Pharmaceuticals Q2 Earnings Call Highlights". Lexicon Pharmaceuticals reported a wider second-quarter loss as revenue declined sharply year over year. The company highlighted completed enrollment in its Phase III SONATA-HCM trial and outlined plans to resubmit a new drug application for ZYNQUISTA in type 1 diabetes during the fourth quarter.

Company

About Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases, particularly in cardiometabolic and neurological areas. It offers Sotagliflozin, marketed as Inpefa and Zynquista, an oral dual SGLT1/2 inhibitor that reduces the risk of cardiovascular death, heart failure hospitalization, and urgent heart failure visits in adults with heart failure, type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors. The company advances key drug candidates including pilavapadin (LX9211) for diabetic peripheral neuropathic pain, with Phase 3 development cleared by the U.S. FDA following positive Phase 2b results, and LX9851, a first-in-class ACSL5 inhibitor for obesity and cardiometabolic disorders exclusively licensed to Novo Nordisk. Additional pipeline efforts target hypertrophic cardiomyopathy with sotagliflozin in the ongoing SONATA-HCM Phase 3 study. Founded in 1995 and headquartered in The Woodlands, Texas, Lexicon Pharmaceuticals leverages its genomics platform to identify novel small-molecule therapies addressing unmet needs in chronic pain and cardiometabolic conditions.

CEO Dr. Michael S. Exton Ph.D. · 81 employees · United States · https://www.lexpharma.com